Parkinson’s Treatments Go After Genetic Targets
Researchers at AAT-AD/PD discussed investigational PD treatments that aim to modify disease by hitting genetic risk factors.
ALL NEWS
5752 RESULTS
Sort By:
- Most Recent
- Most Commented
Antibody Against α-Synuclein Looks Safe In Phase 1
Treatments targeting the main pathological protein of Parkinson’s disease are moving toward the clinic, with two immunotherapies passing Phase 1 safety benchmarks.
Parsing How Alzheimer’s Genetic Risk Works Through Microglia
Scientists at AD/PD 2019 see a Goldilocks of microglial activation: Both too little and too much is bad in an injured brain. How could a therapy make it just right?
No Skin Off Your Nose: New Way to Diagnosing Parkinson’s?
Two papers report that skin samples from people with Parkinson’s disease contain α-synuclein seeds that can be robustly amplified, paving the way for a reliable test for the disease.
Curbing Fatty Acids Means No Parkinson’s—If You Are a Mouse
Reducing levels of monounsaturated fatty acids lowered α-synuclein toxicity and prevented movement symptoms in mice. Scientists say the data boost the α-synuclein tetramer hypothesis.
Better than Crystal Clear? Cryo-EM Achieves Atomic Resolution
Armed with snazzy new hardware, scientists solve protein structures to a resolution of 1.22Å. Cryo-EM now rivals X-ray crystallography.
Help for Speech, Swallowing, and Salivation Problems in ALS
Studies find that a drug in cough syrup can improve symptoms, and that radiation therapy safely shuts off a salivary gland.
New Rodent Knock-Ins Carry Humanized Wild-Type APP
Three amino acid substitutions in the Aβ sequence accelerate BACE cleavage of APP and ramp up Aβ production in rats and mice. The mice can serve as better controls for mutant APP knock-ins already in use.
In APP Knock-In Mice, Spatial Mapping Circuitry Crumbles
Poor coordination among grid cells in the entorhinal cortex and place cells in the hippocampus compromises navigation. Grid cells fail first.
The Microbiome and Disease—What Does Poop Have to Do With It?
Simple lifestyle factors such as alcohol consumption and stool quality alter gut flora. Research on the microbiome and disease should account for those factors, a study reports.
Lilly Teams Up With AstraZeneca for BACE Inhibitor Phase 2/3 Trial
The pharma giant puts up funding to help develop AstraZeneca’s inhibitor, the second such compound to enter Phase 2 testing.
BAN2401 Forges AHEAD into Phase 3, Preclinical AD
The anti-Aβ biologic will be put to the test in two stages of preclinical Alzheimer’s, designated by amyloid load. The long-dormant “est” PET tracer, NAV4694, is on board to make sensitive measurements.
BANish Aβ? BAN2401 Antibody Makes Its Move in Phase 3 Program
At CTAD, a Phase 2 open-label extension of this anti- Aβ protofibril antibody posted data as expected, and new Phase 3 trials for people with early and preclinical Alzheimer’s were described.
TRC-PAD Funnel Finally Touches Down
After years of building an online registry, designing selection algorithms, and getting sites up and running, COVID-19 nearly derailed this trial-ready cohort once again. Now, the first participants have reached the final queue.
Two New Developments in the Search for Alzheimer's Biomarkers
One of the most coveted achievements AD researchers are striving for these days is to develop a biomarker that could, simply and inexpensively, detect if a person has early Alzheimer's disease...
Current Filters
- Date Range : All x